-
-
Eric Topol, MD, chief academic officer of the Cleveland Clinic, said during the Clinic-sponsored Medical Innovation Summit here in mid-October that those involved with or interested in innovation need to get away from the idea that every drug and device needs to be a blockbuster product.
-
E-Z-EM (Lake Success, New York) reported that the spin-off of its AngioDynamics subsidiary has been completed. On Oct. 30, E-Z-EM distributed 0.856377 of a share of AngioDynamics common stock as a dividend on each outstanding share of E-Z-EM common stock to E-Z-EM shareholders of record as of Oct. 11. E-Z-EM shareholders received cash in lieu of any fractional shares.
-
Arrow International (Reading, Pennsylvania) reported the promotion of several executives to positions of new responsibility and the retirement of Philip Fleck, president and chief operating officer, effective Dec. 31.
-
American women are one step closer to having a contraceptive implant option with the recent Food and Drug Administration (FDA) issuance of approvable status for Implanon, the single-rod contraceptive implant from Organon (West Orange, NJ).
-
You suspect that your 17-year-old patient may have a chlamydia infection. Thanks to a nucleic acid amplification screen on a urine specimen, you are able to detect the sexually transmitted disease (STD) and report the results the next day.
-
Research has been a cornerstone of contraceptive technology; the following noninclusive list includes 25 articles of note from the past 25 years. Several selections are offered by Deborah Kowal, MA, adjunct assistant professor in the Rollins School of Public Health at Emory University in Atlanta, co-author of Contraceptive Technology, and the first editor for Contraceptive Technology Update.
-
When the first combined oral contraceptive entered the marketplace in 1960, women began taking hormonally active pills for 21 days, followed by seven days of placebo pills, or no pills at all. This 21/7 regimen resulted in regular withdrawal bleeding every month. Such regular monthly cycles are a modern phenomenon.
-
-
Look ahead five to 10 years, and you may see a male contraceptive on the market, as well as a microbicide for women that offers contraception as well as female-controlled protection against HIV and other sexually transmitted diseases (STDs), say reproductive health experts.
